Jefferies assumed coverage of Immatics (IMTX) with a Buy rating and $18 price target The firm thinks the company is at an inflection point. The company’s cutaneous melanoma readout this year “is a major de-risking point” for the Jefferies’ work suggests a high likelihood of success, the analyst tells investors in a research note. The firm believes this alone can drive near-term upside in the shares.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IMTX:
- Immatics Confirms 2027 Anzu-cel Launch Timeline as PRAME Franchise and Cash Runway Advance
- Immatics sees cash runway into 2028
- Immatics reports FY25 EPS (EUR 1.61) vs. EUR 0.14 last year
- Immatics price target raised to $25 from $23 at Mizuho
- Immatics’ treatment of Stage II and higher CM granted FDA orphan designation